GRPR-targeted radioligands may help to solve, at least in part, these clinical issues by complementing the PSMA PET/CT and radioligand therapy and improving the prostate cancer detection rate as well as therapeutic efficacy. This evidence concerns the gene FOLH1 and prostate cancer.